Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Bridget Westerman

Physician Assistant Buffalo, NY Physician Assistant

NPI 1356919849 CMS profile 11206245

726 Exchange St Ste 710, Buffalo, NY 14201

Open in the dashboard

General payments

$6,247

433 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Bridget Westerman of Buffalo, NY is reported in the CMS Open Payments database as having received $6,247 across 433 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,445 92
2023 General $2,032 124
2022 General $2,020 176
2021 General $751 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bridget Westerman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bridget Westerman were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bridget Westerman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $751 $132 $37–$438 $132
2022 $2,020 $155 $48–$522 $149
2023 $2,032 $167 $52–$557 $160
2024 $1,445 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Janssen Biotech, Inc. $1,523 134 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,306 132 payments
  3. QOL Medical, LLC $736 36 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $567 29 payments
  5. Celgene Corporation $409 29 payments
  6. Pfizer Inc. $369 24 payments
  7. AbbVie, Inc. $300 16 payments
  8. Ferring Pharmaceuticals Inc. $145 3 payments
  9. Phathom Pharmaceuticals, Inc. $125 1 payment
  10. Janssen Scientific Affairs, LLC $125 1 payment
  11. Other $640 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $6,056 430 payments
  2. Education $191 3 payments
Products named General payments · program years 2021–2024
  1. STELARA $1,636 134 payments
  2. XIFAXAN $1,537 154 payments
  3. ZEPOSIA $505 30 payments
  4. ENTYVIO $428 18 payments
  5. Sucraid Therapy For Csid $401 14 payments
  6. PLENVU $351 34 payments
  7. Sucraid Therapy For Csid $336 22 payments
  8. XELJANZ $237 16 payments
  9. REBYOTA $130 2 payments
  10. VOQUEZNA $125 1 payment
  11. Other $1,279 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,563

Median for Physician Assistant: 241

Drug cost

$1,834,156

Median for Physician Assistant: $4,110

Branded share of claims

28.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 36 $1,062,616
Xifaxan Rifaximin Brand 60 $205,300
Creon Lipase/Protease/Amylase Brand 64 $156,793
Linzess Linaclotide Brand 163 $122,734
Sandostatin Lar Depot Octreotide Acetate,mi-Spheres Brand 23 $101,477
Trulance Plecanatide Brand 38 $25,209
Mesalamine Generic 34 $23,028
Motegrity Prucalopride Succinate Brand 32 $19,399
Voquezna Vonoprazan Fumarate Brand 18 $18,869
Dexlansoprazole Dr Dexlansoprazole Brand 31 $12,559

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$11,298

Medicare's payments for the services billed

Medicare patients

117

Average age 66

Services billed

178

69 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 44%
Depression 36%
Chronic kidney disease 34%
Diabetes 26%
Ischemic heart disease 26%
Heart failure 21%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $646
$646 36 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $193
$193 60 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 18 —
Sucraid
  • QOL Medical, LLC $114
$114 — —
DUPIXENT
  • GENZYME CORPORATION $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record